Literature DB >> 25981636

Successful Combination of Sequential Gene Therapy and Rescue Allo-HSCT in Two Children with X-CGD - Importance of Timing.

Ulrich Siler, Anna Paruzynski, Heidi Holtgreve-Grez, Elena Kuzmenko, Ulrike Koehl, Eleonore D Renner, Canan Alhan, Arjan A van de Loosdrecht, Joachim Schwäble, Thomas Pfluger, Joelle Tchinda, Markus Schmugge, Anna Jauch, Sonja Naundorf, Klaus Kühlcke, Gundula Notheis, Tayfun Güngor, Christof V Kalle, Manfred Schmidt, Manuel Grez, Reinhard Seger, Janine Reichenbach1.   

Abstract

We report on a series of sequential events leading to long-term survival and cure of pediatric X-linked chronic granulomatous disease (X-CGD) patients after gamma-retroviral gene therapy (GT) and rescue HSCT. Due to therapyrefractory life-threatening infections requiring hematopoietic stem cell transplantation (HSCT) but absence of HLAidentical donors, we treated 2 boys with X-CGD by GT. Following GT both children completely resolved invasive Aspergillus nidulans infections. However, one child developed dual insertional activation of ecotropic viral integration site 1 (EVI1) and signal transducer and activator of transcription 3 (STAT3) genes, leading to myelodysplastic syndrome (MDS) with monosomy 7. Despite resistance to mismatched allo-HSCT with standard myeloablative conditioning, secondary intensified rescue allo-HSCT resulted in 100 % donor chimerism and disappearance of MDS. The other child did not develop MDS despite expansion of a clone with a single insertion in the myelodysplasia syndrome 1 (MDS1) gene and was cured by early standard allo-HSCT. The slowly developing dominance of clones harboring integrations in MDS1-EVI1 may guide clinical intervention strategies, i.e. early rescue allo-HSCT, prior to malignant transformation. GT was essential for both children to survive and to clear therapy-refractory infections, and future GT with safer lentiviral self-inactivated (SIN) vectors may offer a therapeutic alternative for X-CGD patients suffering from life-threatening infections and lacking HLA-identical HSC donors.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25981636     DOI: 10.2174/1566523215666150515145255

Source DB:  PubMed          Journal:  Curr Gene Ther        ISSN: 1566-5232            Impact factor:   4.391


  27 in total

1.  Adeno-Associated Virus-Based Gene Therapy for Lifelong Correction of Genetic Disease.

Authors:  Christian M Brommel; Ashley L Cooney; Patrick L Sinn
Journal:  Hum Gene Ther       Date:  2020-08-21       Impact factor: 5.695

2.  CRISPR-Mediated Knockout of Cybb in NSG Mice Establishes a Model of Chronic Granulomatous Disease for Human Stem-Cell Gene Therapy Transplants.

Authors:  Colin L Sweeney; Uimook Choi; Chengyu Liu; Sherry Koontz; Seung-Kwon Ha; Harry L Malech
Journal:  Hum Gene Ther       Date:  2017-03-06       Impact factor: 5.695

3.  Lentiviral Transfer of γ-Globin with Fusion Gene NUP98-HOXA10HD Expands Hematopoietic Stem Cells and Ameliorates Murine β-Thalassemia.

Authors:  Hui Fen Zhao; Allistair Abraham; Yoon-Sang Kim; Yong-Dong Wang; Tamara Pestina; Jun Zhan; Keith Humphries; Arthur W Nienhuis; Derek A Persons
Journal:  Mol Ther       Date:  2017-02-09       Impact factor: 11.454

4.  Targeted Repair of CYBB in X-CGD iPSCs Requires Retention of Intronic Sequences for Expression and Functional Correction.

Authors:  Colin L Sweeney; Jizhong Zou; Uimook Choi; Randall K Merling; Alexander Liu; Aaron Bodansky; Sandra Burkett; Jung-Woong Kim; Suk See De Ravin; Harry L Malech
Journal:  Mol Ther       Date:  2017-02-01       Impact factor: 11.454

5.  Treatment of primary immunodeficiency with allogeneic transplant and gene therapy.

Authors:  Sung-Yun Pai
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

6.  Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency.

Authors:  Maria Pia Cicalese; Francesca Ferrua; Laura Castagnaro; Roberta Pajno; Federica Barzaghi; Stefania Giannelli; Francesca Dionisio; Immacolata Brigida; Marco Bonopane; Miriam Casiraghi; Antonella Tabucchi; Filippo Carlucci; Eyal Grunebaum; Mehdi Adeli; Robbert G Bredius; Jennifer M Puck; Polina Stepensky; Ilhan Tezcan; Katie Rolfe; Erika De Boever; Rickey R Reinhardt; Jonathan Appleby; Fabio Ciceri; Maria Grazia Roncarolo; Alessandro Aiuti
Journal:  Blood       Date:  2016-04-29       Impact factor: 22.113

Review 7.  Retroviral Insertional Mutagenesis in Humans: Evidence for Four Genetic Mechanisms Promoting Expansion of Cell Clones.

Authors:  Frederic D Bushman
Journal:  Mol Ther       Date:  2020-01-07       Impact factor: 11.454

8.  Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency.

Authors:  Thomas A Fox; Ronjon Chakraverty; Siobhan Burns; Benjamin Carpenter; Kirsty Thomson; David Lowe; Adele Fielding; Karl Peggs; Panagiotis Kottaridis; Benjamin Uttenthal; Venetia Bigley; Matthew Buckland; Victoria Grandage; Shari Denovan; Sarah Grace; Julia Dahlstrom; Sarita Workman; Andrew Symes; Stephen Mackinnon; Rachael Hough; Emma Morris
Journal:  Blood       Date:  2017-12-26       Impact factor: 25.476

Review 9.  Update on Clinical Ex Vivo Hematopoietic Stem Cell Gene Therapy for Inherited Monogenic Diseases.

Authors:  Francesca Tucci; Samantha Scaramuzza; Alessandro Aiuti; Alessandra Mortellaro
Journal:  Mol Ther       Date:  2020-11-20       Impact factor: 11.454

10.  A comparison of foamy and lentiviral vector genotoxicity in SCID-repopulating cells shows foamy vectors are less prone to clonal dominance.

Authors:  Elizabeth M Everson; Miles E Olzsko; David J Leap; Jonah D Hocum; Grant D Trobridge
Journal:  Mol Ther Methods Clin Dev       Date:  2016-08-17       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.